Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Saharinen, T. Tammela, M. Karkkainen, K. Alitalo (2004)
Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation.Trends in immunology, 25 7
M. Raica, A. Cîmpean, D. Ribatti (2008)
The role of podoplanin in tumor progression and metastasis.Anticancer research, 28 5B
R. Kalluri, M. Zeisberg (2006)
Fibroblasts in cancerNature Reviews Cancer, 6
T. Nielsen, Forrest Hsu, Kristin Jensen, Maggie Cheang, G. Karaca, Zhiyuan Hu, T. Hernandez-Boussard, C. Livasy, D. Cowan, L. Dressler, L. Akslen, J. Ragaz, A. Gown, C. Gilks, M. Rijn, C. Perou (2004)
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast CarcinomaClinical Cancer Research, 10
C. Anders, L. Carey (2009)
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.Clinical breast cancer, 9 Suppl 2
S. Schoppmann, A. Berghoff, C. Dinhof, R. Jakesz, M. Gnant, P. Dubsky, Bettina Jesch, H. Heinzl, P. Birner (2012)
Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancerBreast Cancer Research and Treatment, 134
M. Raica, A. Cîmpean, R. Ceaușu, D. Ribatti (2011)
Lymphatic microvessel density, VEGF-C, and VEGFR-3 expression in different molecular types of breast cancer.Anticancer research, 31 5
R. Theriault, J. Litton, E. Mittendorf, Huiqin Chen, F. Meric-Bernstam, M. Chávez-MacGregor, P. Morrow, W. Woodward, A. Sahin, G. Hortobagyi, A. González-Angulo (2011)
Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype.Clinical breast cancer, 11 5
W. Kanner, M. Galgano, K. Atkins (2010)
Podoplanin Expression in Basal and Myoepithelial Cells: Utility and Potential PitfallsApplied Immunohistochemistry & Molecular Morphology, 18
Anna Britto, A. Schenka, Natália Moraes-Schenka, M. Alvarenga, J. Shinzato, J. Vassallo, L. Ward (2009)
Immunostaining with D2–40 improves evaluation of lymphovascular invasion, but may not predict sentinel lymph node status in early breast cancerBMC Cancer, 9
A. Kawase, G. Ishii, K. Nagai, Takeo Ito, T. Nagano, Y. Murata, T. Hishida, M. Nishimura, J. Yoshida, Kazuya Suzuki, A. Ochiai (2008)
Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinomaInternational Journal of Cancer, 123
Ester Martín-Villar, D. Megías, S. Castel, M. Yurrita, S. Vilaró, M. Quintanilla (2006)
Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transitionJournal of Cell Science, 119
Beatriz Fernández-Muñoz, M. Yurrita, Ester Martín-Villar, Patricia Carrasco-Ramírez, D. Megías, J. Renart, M. Quintanilla (2011)
The transmembrane domain of podoplanin is required for its association with lipid rafts and the induction of epithelial-mesenchymal transition.The international journal of biochemistry & cell biology, 43 6
(2008)
Lymph vascular invasion in invasive mammary carcinomas identified by the endothelial lymphatic marker D2-40 is associated with other indicators of poor prognosis
Ester Martín-Villar, Beatriz Fernández-Muñoz, M. Parsons, M. Yurrita, D. Megías, E. Pérez-Gómez, G. Jones, M. Quintanilla (2010)
Podoplanin Associates with CD44 to Promote Directional Cell MigrationMolecular Biology of the Cell, 21
R. Mohammed, I. Ellis, Ali Mahmmod, E Hawkes, A. Green, E. Rakha, Stewart Martin (2011)
Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significanceModern Pathology, 24
A. Wicki, François Lehembre, N. Wick, B. Hantusch, D. Kerjaschki, G. Christofori (2006)
Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton.Cancer cell, 9 4
Angel Arnaout-Alkarain, H. Kahn, S. Narod, P. Sun, Alexander Marks (2007)
Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancerModern Pathology, 20
S. Schoppmann, M. Schindl, S. Breiteneder-Geleff, A. Soleima, G. Breitenecker, B. Karner, P. Birner (2001)
Inflammatory stromal reaction correlates with lymphatic microvessel density in early-stage cervival cancer.Anticancer research, 21 5
S. Schoppmann, G. Bayer, K. Aumayr, S. Taucher, S. Geleff, M. Rudas, E. Kubista, H. Hausmaninger, H. Samonigg, M. Gnant, R. Jakesz, R. Horvat (2004)
Prognostic Value of Lymphangiogenesis and Lymphovascular Invasion in Invasive Breast CancerAnnals of Surgery, 240
B. Puła, Aleksandra Jethon, A. Piotrowska, A. Gomułkiewicz, Tomasz Owczarek, J. Calik, A. Wojnar, W. Witkiewicz, J. Ryš, M. Ugorski, P. Dzięgiel, M. Podhorska‐Okołów (2011)
Podoplanin expression by cancer‐associated fibroblasts predicts poor outcome in invasive ductal breast carcinomaHistopathology, 59
M. Braun, U. Flucke, Manuel Debald, G. Walgenbach-Bruenagel, K. Walgenbach, T. Höller, M. Pölcher, M. Wolfgarten, A. Sauerwald, M. Keyver-Paik, M. Kuehr, R. Büttner, W. Kuhn (2008)
Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin): a clinically useful predictor for axillary lymph node metastasesBreast Cancer Research and Treatment, 112
E. Rakha, M. El-Sayed, A. Green, Andrew Lee, J. Robertson, I. Ellis (2007)
Prognostic markers in triple‐negative breast cancerCancer, 109
H. Chauhan, A. Abraham, J. Phillips, J. Pringle, R. Walker, J. Jones (2003)
There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesionsJournal of Clinical Pathology, 56
T. Tot (2011)
Early and more advanced unifocal and multifocal breast carcinomas and their molecular phenotypes.Clinical breast cancer, 11 4
N. Christiansen, Lei Chen, J. Gilmore, David Pechar, Stephen Szabo (2012)
Association between African American race and outcomes in patients with nonmetastatic triple-negative breast cancer: a retrospective analysis by using results from the Georgia Cancer Specialist Database.Clinical breast cancer, 12 4
A. Wicki, G. Christofori (2006)
The potential role of podoplanin in tumour invasionBritish Journal of Cancer, 96
E. Rakha, T. Putti, DM El‐Rehim, C. Paish, A. Green, D. Powe, Ahs Lee, J. Robertson, I. Ellis (2006)
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiationThe Journal of Pathology, 208
S. El-Gendi, M. Abdel-Hadi (2009)
Lymphatic vessel density as prognostic factor in breast carcinoma: relation to clinicopathologic parameters.Journal of the Egyptian National Cancer Institute, 21 2
M. Ito, T. Moriya, T. Ishida, Shin Usami, A. Kasajima, H. Sasano, N. Ohuchi (2007)
Significance of pathological evaluation for lymphatic vessel invasion in invasive breast cancerBreast Cancer, 14
RESEARCH ARTICLE Triple-negative, Basal Marker-expressing, and High-grade Breast Carcinomas are Characterized by High Lymphatic Vessel Density and the Expression of Podoplanin in Stromal Fibroblasts Joanna A. Niemiec, PhD,* Agnieszka Adamczyk, PhD,* Aleksandra Ambicka, MD,w Anna Mucha-Ma!ecka, MD, PhD,z Wojciech M. Wysocki, MD, PhD,y and Janusz Rys´, MD, PhDw Key Words: breast cancer, podoplanin, lymphatic vessel density, Abstract: Podoplanin, expressed in the lymphatic but not in the basal subtype, basal markers blood vessel endothelium, is widely used as a specific marker for (Appl Immunohistochem Mol Morphol 2014;22:10–16) lymphatic endothelial cells and lymphangiogenesis. The relation between lymphatic vessel density and breast cancer subtype or the expression of basal markers has not yet been investigated. We assessed lymphatic vessel density (LVD), blood vessel den- ymphatic vessels are one of the principal routes for sity, and the expression of podoplanin in stromal cancer-asso- Lbreast cancer dissemination. Podoplanin, vascular ciated fibroblasts, in 156 invasive ductal breast cancers (TZ1, endothelial growth factor receptor-3 (VEGFR-3), Prox-1 NZ1, M0). Afterwards, we assessed the relationship between and desmoplakin are lymphatic vessel markers, playing the above-mentioned parameters and (i) breast cancer subtype multiple roles in the physiological and pathological 2,3 (luminal vs. HER2 vs. triple negative), (ii) tumor grade
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Jan 1, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.